QUOTE AND NEWS
DailyFinance  10 hrs ago  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy...
StreetInsider.com  10 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sucampo+Pharma+%28SCMP%29%2C+Takeda+Launch+AMITIZA+D-t-C+Ad+Campaign/9865689.html for the full story.
GenEng News  Sep 26  Comment 
Takeda Pharmaceutical has teamed up with BioMotiv to identify and develop new therapeutics under a partnership that will generate at least 25 oku-yen (about $25 million) over five years from the pharma giant to the biotech...
FiercePharma  Sep 17  Comment 
Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could...
FiercePharma  Sep 16  Comment 
Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up. And now, as promised, the blueprints for a new,...
FiercePharma  Sep 11  Comment 
Yesterday, Orexigen won FDA approval for its obesity drug Contrave, but with a "black box" warning on side effects. And patients could have yet another weight-loss choice, as a panel of FDA advisers meet today to weigh Novo Nordisk's rival drug,...
Benzinga  Sep 11  Comment 
Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an...
Forbes  Sep 10  Comment 
The FDA announced today that it had approved Contrave, the long-awaited and much-disputed weight loss drug.  The drug is a combination of two drugs already approved for other indications: naltrexone hydrochloride, which is used to combat alcohol...
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Orexigen+Therapeutics+%28OREX%29%2C+Takeda+Enter+Manufacturing+Services+Agreement+Covering+NB32/9814894.html for the full story.
GenEng News  Sep 3  Comment 
AbbVie will join Infinity Pharmaceuticals to develop and commercialize the latter’s lead R&D program, focused on the cancer compound duvelisib (IPI-145), the companies said today. The deal could generate up to $805 million for Infinity, which...




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki